Introduction

Functional dyspepsia (FD) is one of the most prevalent disorders of gut-brain interaction (DGBI), classified under the Rome IV framework as category B1. It is defined by bothersome symptoms originating in the gastroduodenal region in the absence of any organic, systemic, or metabolic disease that is likely to explain those symptoms. The term "dyspepsia" derives from the Greek dys (difficult) and pepsis (digestion), and patients with this condition describe a constellation of upper abdominal complaints that may include postprandial fullness, early satiation, epigastric pain, and epigastric burning.

Functional dyspepsia represents a significant clinical and economic burden worldwide. It accounts for a substantial proportion of outpatient gastroenterology consultations and is associated with reduced quality of life, workplace productivity loss, and considerable healthcare expenditure. Despite its high prevalence, functional dyspepsia remains underrecognized and frequently mismanaged, in part because its symptom profile overlaps with numerous organic conditions and because no single biomarker or diagnostic test can confirm the diagnosis. The Rome IV criteria, published in 2016 by the Rome Foundation, provide the current international standard for a symptom-based, positive diagnosis of functional dyspepsia.

Historical Context and Evolution of Dyspepsia Classification

The concept of dyspepsia as a clinical entity has evolved substantially over the past several decades. Early classifications grouped all upper gastrointestinal symptoms under an undifferentiated "dyspepsia" umbrella, making little distinction between structural and functional etiologies. The Rome process, initiated in 1989, brought rigor to the categorization of functional gastrointestinal disorders by developing symptom-based diagnostic criteria analogous to those used in other areas of medicine.

Rome I (1994) introduced the concept of functional dyspepsia as a distinct entity separate from organic causes such as peptic ulcer disease and gastroesophageal reflux disease (GERD). Rome II (1999) attempted to subdivide dyspepsia into ulcer-like, dysmotility-like, and unspecified subtypes, but these categories proved unreliable in clinical practice because symptom patterns did not consistently map to underlying pathophysiological mechanisms.

Rome III (2006) introduced a more durable subtype classification that persists in Rome IV: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). This framework recognized that patients with meal-related symptoms (postprandial fullness and early satiation) may differ pathophysiologically from those with pain or burning that is not necessarily related to meals. However, Rome III also acknowledged that substantial overlap between subtypes is common.

Rome IV (2016) refined the functional dyspepsia criteria in several important ways. It replaced the term "functional gastrointestinal disorders" with "disorders of gut-brain interaction" to better reflect the bidirectional communication between the central nervous system and the gut that underlies these conditions. It emphasized that the qualifying symptoms must be "bothersome" to the patient, setting a clinically meaningful threshold that prevents trivial or incidental symptoms from triggering a diagnosis. It also clarified the temporal criteria and maintained the PDS/EPS subtype framework while acknowledging that overlap between subtypes occurs in 30% to 50% of patients in clinical practice.

The Rome IV Diagnostic Criteria for Functional Dyspepsia (B1)

The formal Rome IV diagnostic criteria for functional dyspepsia require the following:

At least one of the following bothersome symptoms must be present:

1. Bothersome postprandial fullness
2. Bothersome early satiation
3. Bothersome epigastric pain
4. Bothersome epigastric burning

AND:

• No evidence of organic, systemic, or metabolic disease that is likely to explain the symptoms (including at upper endoscopy when clinically indicated).

Temporal requirement:

• Criteria must be fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.

All three components (at least one cardinal symptom, exclusion of organic disease, and temporal criteria) must be simultaneously satisfied for a positive diagnosis. A patient who has bothersome symptoms but has not been evaluated for organic causes, or whose symptoms have been present for fewer than three months, does not yet qualify for the diagnosis of functional dyspepsia under Rome IV.

The Four Cardinal Symptoms

Bothersome Postprandial Fullness

Postprandial fullness refers to an unpleasant sensation of prolonged food retention in the stomach after eating. Patients typically describe it as a feeling that the meal "sits" in the upper abdomen for an abnormally long time, often accompanied by upper abdominal distension or heaviness. Under Rome IV, this symptom must be "bothersome," meaning it is severe enough to affect the patient's daily activities, eating habits, or quality of life. Mild, transient fullness after a large or rich meal that does not impact function does not meet this threshold.

Postprandial fullness is one of the defining features of the postprandial distress syndrome (PDS) subtype. Pathophysiologically, it is often associated with impaired gastric accommodation (the ability of the proximal stomach to relax and expand to receive a meal) and delayed gastric emptying, although the correlation between symptom severity and measurable motility abnormalities is imperfect. Some patients with severe postprandial fullness have normal gastric emptying times, and some patients with objectively delayed emptying report minimal fullness.

Bothersome Early Satiation

Early satiation (sometimes called "early satiety" in older literature, though "satiation" is the preferred Rome IV term) is the sensation of feeling full sooner than expected after beginning a meal. Patients with this symptom report being unable to finish a normal-sized meal or needing to stop eating well before they have consumed the amount they intended. This can lead to reduced caloric intake, unintentional weight loss, and nutritional deficiencies in severe cases.

Early satiation is the second defining feature of PDS. It is thought to relate to impaired fundic accommodation, heightened sensitivity to gastric distension, and possibly altered signaling from gut hormones such as cholecystokinin (CCK), ghrelin, and glucagon-like peptide-1 (GLP-1). Like postprandial fullness, early satiation must be bothersome to qualify under Rome IV.

Bothersome Epigastric Pain

Epigastric pain is defined as a subjectively unpleasant sensation in the epigastrium (the upper central region of the abdomen, between the costal margins and the umbilicus). The pain may be described as sharp, dull, gnawing, or aching. It may occur in the fasting state, after meals, or both, and may or may not be relieved by eating or by antacid medications. Under Rome IV, this pain must be bothersome and localized to the epigastrium; diffuse abdominal pain or pain in other quadrants does not qualify.

Epigastric pain is one of the two defining features of the epigastric pain syndrome (EPS) subtype. It is often attributed to duodenal or gastric hypersensitivity (visceral hyperalgesia), impaired central pain modulation, and low-grade duodenal inflammation. In clinical practice, epigastric pain is also the symptom most likely to overlap with organic conditions such as peptic ulcer disease, biliary colic, and pancreatic disorders, which is why appropriate investigation (particularly upper endoscopy) is important before attributing the symptom to functional dyspepsia.

Bothersome Epigastric Burning

Epigastric burning is a sensation of heat or burning localized to the epigastrium. It differs from heartburn, which is a retrosternal burning sensation that characterizes gastroesophageal reflux disease (GERD). The anatomical localization is key: burning felt behind the sternum suggests GERD, while burning felt in the epigastric region fits the functional dyspepsia construct. However, overlap between GERD and functional dyspepsia is common, and up to 30% to 40% of patients with functional dyspepsia may also have concurrent GERD symptoms.

Epigastric burning is the second defining feature of EPS. Its pathophysiology likely involves gastric and duodenal mucosal hypersensitivity, potentially mediated by acid exposure, altered mucosal integrity, or sensitization of visceral afferent neurons. Some patients with epigastric burning respond well to acid-suppressive therapy, while others derive no benefit, reflecting the heterogeneity of underlying mechanisms.

Exclusion of Organic Disease

A critical component of the Rome IV criteria is the requirement that no organic, systemic, or metabolic disease is identified that is likely to explain the patient's symptoms. This does not necessarily mandate an exhaustive battery of tests for every patient; rather, it requires that clinically appropriate evaluation has been undertaken based on the individual patient's presentation, age, risk factors, and the presence or absence of alarm features.

Upper endoscopy (esophagogastroduodenoscopy, or EGD) is the most commonly performed investigation and is generally recommended in patients over age 60 with new-onset dyspepsia, those with alarm features, and those who have failed empiric therapy. In younger patients without alarm features, a test-and-treat approach for Helicobacter pylori or an empiric trial of proton pump inhibitor (PPI) therapy is often pursued before endoscopy.

Organic conditions that must be excluded or considered include:

• Peptic ulcer disease: Gastric or duodenal ulcers identified on endoscopy, often associated with H. pylori infection or NSAID use.
• Gastric or esophageal malignancy: Particularly in older patients or those with alarm features such as unintentional weight loss, dysphagia, or iron deficiency anemia.
• Eosinophilic esophagitis or eosinophilic gastroenteritis: Increasingly recognized causes of upper GI symptoms requiring mucosal biopsies for diagnosis.
• Celiac disease: Can present with dyspeptic symptoms; serologic screening with tissue transglutaminase IgA (tTG-IgA) should be considered.
• Biliary and pancreatic disorders: Gallstone disease, chronic pancreatitis, and pancreatic malignancy can mimic epigastric pain.
• Gastroparesis: Severely delayed gastric emptying may produce symptoms overlapping with functional dyspepsia; a gastric emptying study (scintigraphy) can differentiate the two when clinical suspicion is high, although the distinction is debated as a continuum rather than a binary division.
• Medication-related dyspepsia: NSAIDs, aspirin, iron supplements, bisphosphonates, potassium chloride, erythromycin, and many other drugs can cause dyspeptic symptoms.
• Systemic and metabolic conditions: Diabetes mellitus (especially with autonomic neuropathy), thyroid disorders, adrenal insufficiency, and connective tissue diseases may contribute to upper GI symptoms.

It is important to note that the Rome IV criteria use the phrase "likely to explain," not "capable of causing." This acknowledges that some patients may have incidental findings (e.g., a small hiatal hernia, mild gastritis without H. pylori) that are common in the general population and are not considered sufficient to explain bothersome dyspeptic symptoms. Clinical judgment is required to determine whether a finding is truly explanatory or incidental.

Temporal Criteria

The Rome IV temporal requirement for functional dyspepsia mandates that the diagnostic criteria must have been fulfilled for the last three months, and symptom onset must have occurred at least six months before the time of diagnosis. This dual gate serves multiple purposes:

• Establishes chronicity: The three-month duration requirement ensures the condition is persistent rather than self-limited. Acute dyspepsia from viral gastroenteritis, medication exposure, or dietary indiscretion is excluded by this time filter.
• Confirms an established pattern: The six-month onset requirement ensures that symptoms are not part of a new or rapidly evolving clinical picture that might represent an emerging organic disease.
• Reduces diagnostic uncertainty: Conditions such as peptic ulcer disease, early malignancy, or new-onset celiac disease may initially present with dyspeptic symptoms that evolve or develop additional features over time. The temporal criteria allow for a period of observation and appropriate investigation.

In practice, a patient presenting with epigastric pain that began two months ago would not meet the six-month onset criterion, regardless of how classic the symptoms appear. Conversely, a patient who has experienced intermittent postprandial fullness for the past year, with the symptoms continuously meeting criteria over the most recent three months, would satisfy both temporal requirements.

Subtypes: Postprandial Distress Syndrome and Epigastric Pain Syndrome

Once a patient meets the Rome IV criteria for functional dyspepsia, the condition is further subclassified into one of two subtypes (or their overlap) based on the predominant symptom pattern. This subtype classification carries implications for pathophysiology, prognosis, and treatment selection.

Postprandial Distress Syndrome (PDS, B1a)

PDS is defined by the presence of bothersome postprandial fullness (occurring after ordinary-sized meals, at least several times per week) and/or bothersome early satiation (preventing finishing a regular meal, at least several times per week). The symptoms are meal-related, typically worsening during or shortly after eating, and may be associated with upper abdominal bloating, nausea, or excessive belching.

PDS is the more common subtype, accounting for approximately 60% to 70% of functional dyspepsia cases in population-based studies. Pathophysiologically, PDS is associated with impaired gastric accommodation, delayed gastric emptying (present in 20% to 40% of patients), and heightened sensitivity to gastric distension. Prokinetic agents, fundic relaxors, and dietary modifications (smaller, more frequent meals; avoidance of high-fat foods) are often prioritized in management.

Epigastric Pain Syndrome (EPS, B1b)

EPS is defined by the presence of bothersome epigastric pain (at least one day per week) and/or bothersome epigastric burning (at least one day per week). These symptoms may or may not be related to meals and may occur in the fasting state. They are not generalized (i.e., they are localized to the epigastrium) and are not fulfilling criteria for biliary pain.

EPS accounts for approximately 20% to 30% of functional dyspepsia cases as a standalone subtype. Its pathophysiology is more closely linked to duodenal hypersensitivity, altered acid perception, low-grade duodenal inflammation (including increased duodenal eosinophils), and impaired central pain modulation. Acid-suppressive therapy (PPIs or H2-receptor antagonists) and central neuromodulators (tricyclic antidepressants, mirtazapine) are often prioritized for EPS.

Overlap PDS-EPS

A significant proportion of patients (30% to 50% in clinical series) exhibit features of both PDS and EPS simultaneously. These overlap patients tend to have more severe symptoms, greater healthcare utilization, and more psychological comorbidity than patients with a single subtype. The Rome IV framework classifies these patients as having both subtypes rather than creating a separate "overlap" category. Management in overlap patients may require a combination of approaches targeting both meal-related and pain-related symptoms.

Epidemiology

Functional dyspepsia is one of the most common gastrointestinal conditions encountered in clinical practice. Global prevalence estimates vary widely depending on the criteria used (Rome III versus Rome IV, uninvestigated versus investigated dyspepsia) and the population studied, but most meta-analyses report a prevalence of 10% to 20% in Western populations and similar or slightly higher rates in Asian and South American populations.

The condition affects individuals across all age groups but is most commonly diagnosed in younger to middle-aged adults (ages 20 to 50). Women are affected somewhat more frequently than men in most population-based surveys, with female-to-male ratios typically ranging from 1.2:1 to 1.8:1. This sex disparity may reflect differences in visceral sensitivity, hormonal influences, gastric motility patterns, and healthcare-seeking behavior.

Functional dyspepsia carries a substantial economic burden. Direct costs include outpatient visits, endoscopies, laboratory testing, imaging, and medication expenditures. Indirect costs include absenteeism, presenteeism (attending work with reduced productivity), and reduced participation in social and recreational activities. Studies from North America and Europe estimate that the annual per-patient cost of functional dyspepsia (combining direct and indirect expenses) ranges from $1,000 to $5,000, with aggregate national costs reaching billions of dollars.

Risk factors for functional dyspepsia include a history of acute infectious gastroenteritis (post-infectious functional dyspepsia), H. pylori infection, NSAID use, smoking, psychological distress (anxiety, depression, somatization), childhood adversity, and female sex. Dietary factors such as high-fat diets, wheat-containing foods, and coffee may trigger or exacerbate symptoms in susceptible individuals, though these associations are inconsistent across studies.

Pathophysiology

The pathophysiology of functional dyspepsia is multifactorial and heterogeneous. No single mechanism accounts for all cases, and multiple processes often coexist in the same patient. Understanding these mechanisms is essential for rational therapeutic selection.

Impaired Gastric Accommodation

Gastric accommodation is the reflex relaxation of the proximal stomach (fundus) in response to food intake, mediated primarily by vagal pathways and nitric oxide signaling. This process allows the stomach to receive a meal without a significant increase in intragastric pressure. Approximately 40% of functional dyspepsia patients demonstrate impaired gastric accommodation on barostat or SPECT (single-photon emission computed tomography) imaging studies. Impaired accommodation leads to premature redistribution of gastric contents to the distal stomach, contributing to postprandial fullness and early satiation. Impaired accommodation is particularly associated with the PDS subtype.

Delayed Gastric Emptying

Delayed gastric emptying is present in 20% to 40% of functional dyspepsia patients, as measured by gastric scintigraphy or the gastric emptying breath test. When gastric emptying is delayed, food remains in the stomach longer than normal, potentially contributing to postprandial fullness, nausea, bloating, and early satiation. However, the correlation between the degree of delayed emptying and symptom severity is weak, and some patients with marked delay are minimally symptomatic while others with normal emptying have severe symptoms. The Rome IV framework considers functional dyspepsia and gastroparesis as potentially overlapping conditions on a spectrum rather than strictly separate entities.

Visceral Hypersensitivity

Visceral hypersensitivity, defined as an exaggerated perception of normal physiological stimuli within the gastrointestinal tract, is a central feature of many DGBI. In functional dyspepsia, patients may exhibit heightened sensitivity to gastric distension (tested by barostat balloon inflation), acid exposure, nutrient infusion, or duodenal lipid perfusion. This hypersensitivity may result from peripheral sensitization of visceral afferents (e.g., through low-grade inflammation, mast cell activation, or altered mucosal permeability) and/or central amplification of visceral signals in the brain.

Duodenal hypersensitivity to acid and lipid appears to be particularly relevant to EPS. Studies have shown that even small amounts of duodenal acid perfusion can reproduce epigastric pain in functional dyspepsia patients but not in healthy controls, suggesting altered chemo-sensitivity of duodenal mucosal afferents.

Duodenal Low-Grade Inflammation and Eosinophilia

One of the most important pathophysiological insights in recent years has been the identification of low-grade duodenal inflammation in a subset of functional dyspepsia patients. Increased duodenal eosinophil counts (duodenal eosinophilia), elevated mast cell numbers, and increased mucosal permeability have been documented in multiple studies. Eosinophils and mast cells release mediators (histamine, serotonin, prostaglandins, proteases, and cytokines) that can sensitize submucosal sensory nerves and alter motility.

This duodenal micro-inflammation may be triggered or perpetuated by prior infection, food antigens, altered microbiota, impaired mucosal barrier function, or immune dysregulation. The finding has opened new therapeutic avenues, including investigation of anti-eosinophilic agents, mast cell stabilizers, and mucosal protectants in functional dyspepsia.

Helicobacter pylori Infection

H. pylori infection is present in a subset of functional dyspepsia patients and is the only potentially curable cause recognized within the Rome framework. Rome IV and multiple international guidelines recommend a test-and-treat approach for H. pylori in patients with dyspeptic symptoms, particularly in populations with moderate to high prevalence of infection. Eradication of H. pylori leads to sustained symptom improvement in approximately 10% of treated patients compared to placebo (number needed to treat approximately 14). When eradication resolves dyspeptic symptoms and the benefit is sustained for at least six months, Rome IV reclassifies the condition as "H. pylori-associated dyspepsia" rather than functional dyspepsia.

Post-Infectious Functional Dyspepsia

A well-documented subset of functional dyspepsia develops following an episode of acute infectious gastroenteritis. Post-infectious functional dyspepsia is analogous to post-infectious IBS and has been described after bacterial (Salmonella, Campylobacter, E. coli), viral (norovirus, rotavirus), and parasitic infections. The proposed mechanisms include persistent low-grade mucosal inflammation, altered enteroendocrine cell populations (particularly increased duodenal cholecystokinin and serotonin-containing cells), gut microbiota shifts, and sensitization of visceral afferents. The risk of developing functional dyspepsia after acute gastroenteritis is estimated at 2 to 3 times higher than in uninfected individuals, and symptoms may persist for months to years.

Brain-Gut Axis Dysfunction and Psychosocial Factors

Functional dyspepsia is considered a disorder of gut-brain interaction, and central nervous system processes play an important role. Patients with functional dyspepsia have higher rates of anxiety, depression, somatization, and neuroticism compared to healthy controls. Functional neuroimaging studies have demonstrated altered processing of visceral signals in brain regions involved in pain perception, emotional regulation, and interoception (including the anterior cingulate cortex, insula, prefrontal cortex, and amygdala).

Early life adversity, chronic stress, and maladaptive coping styles are also associated with functional dyspepsia. The relationship between psychosocial factors and dyspeptic symptoms is bidirectional: psychological distress can exacerbate gastrointestinal symptoms through descending modulatory pathways, autonomic dysregulation, and altered hypothalamic-pituitary-adrenal (HPA) axis activity, while chronic GI symptoms can themselves generate anxiety, hypervigilance, and depressed mood.

Altered Gut Microbiota

Emerging data suggest that the gastric and duodenal microbiota may be altered in functional dyspepsia, with shifts in microbial composition that differ from healthy controls. While the evidence is less mature than for IBS, studies have identified changes in the relative abundance of specific bacterial taxa in the duodenal mucosa and gastric fluid of functional dyspepsia patients. Whether these changes are causative, consequential, or epiphenomenal remains an active area of investigation.

Clinical Evaluation and Differential Diagnosis

The clinical evaluation of a patient with dyspeptic symptoms should balance thoroughness against the avoidance of unnecessary testing. A structured approach begins with a detailed history, physical examination, and risk stratification for alarm features.

History and Symptom Characterization

The clinician should systematically assess each of the four cardinal symptoms, determining their frequency, severity, relationship to meals, and impact on daily function. The use of validated instruments such as the Nepean Dyspepsia Index (NDI), the Leuven Postprandial Distress Scale, or the Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) can standardize symptom assessment and facilitate longitudinal monitoring.

A thorough medication history is essential, as many drugs can cause or exacerbate dyspepsia. Dietary history may reveal specific triggers (high-fat meals, coffee, alcohol, wheat, spicy foods). Psychosocial assessment should explore anxiety, depression, life stressors, and the patient's illness beliefs and expectations.

Alarm Features

Alarm features that warrant prompt investigation (typically with upper endoscopy) include:

• Unintentional weight loss (more than 5% of body weight)
• Progressive dysphagia or odynophagia
• Persistent vomiting
• Evidence of gastrointestinal bleeding (hematemesis, melena)
• Iron deficiency anemia
• Palpable abdominal mass or lymphadenopathy
• Family history of upper GI malignancy
• New-onset dyspepsia in a patient over age 60

The absence of alarm features does not guarantee a functional etiology, but it does substantially lower the pretest probability of serious organic disease and may allow for a step-up approach (empiric therapy before endoscopy) in appropriate patients.

Recommended Investigations

A reasonable baseline evaluation may include:

• H. pylori testing: Non-invasive options include the urea breath test, stool antigen test, or serology (less preferred due to inability to distinguish active from past infection). Invasive testing via endoscopic biopsy with rapid urease test or histology is performed when EGD is indicated for other reasons.
• Upper endoscopy (EGD): Recommended in patients with alarm features, those over 60 with new-onset symptoms, and those who fail empiric therapy. Biopsies should be obtained from the duodenum (to evaluate for celiac disease, eosinophilic duodenitis, or microscopic duodenitis), gastric antrum and body (for H. pylori and gastric pathology), and esophagus if GERD or eosinophilic esophagitis is suspected.
• Basic blood work: Complete blood count, comprehensive metabolic panel, and celiac serology (tTG-IgA with total IgA).
• Abdominal imaging: Right upper quadrant ultrasound or cross-sectional imaging if biliary or pancreatic pathology is suspected.
• Gastric emptying study: A 4-hour solid-phase gastric scintigraphy should be considered when symptoms are severe, refractory, or suggestive of gastroparesis (prominent nausea, vomiting, postprandial fullness, early satiation). Medications that affect motility (opioids, anticholinergics, GLP-1 receptor agonists) should be withheld before testing.

Key Differential Diagnoses

• Peptic ulcer disease: Gastric or duodenal ulcers, most commonly caused by H. pylori or NSAIDs. Endoscopy is definitive.
• Gastroesophageal reflux disease (GERD): Heartburn and regurgitation predominate, but overlap with FD is common (up to 40% of patients have both).
• Gastroparesis: Severely delayed gastric emptying with prominent nausea and vomiting. Rome IV views gastroparesis and FD as potentially overlapping conditions.
• Celiac disease: May present with dyspeptic symptoms; duodenal biopsies and serologies are diagnostic.
• Eosinophilic esophagitis or gastroenteritis: Requires mucosal biopsies for diagnosis.
• Biliary colic and chronic cholecystitis: Episodic right upper quadrant or epigastric pain, often postprandial, associated with gallstones on imaging.
• Chronic pancreatitis or pancreatic malignancy: Epigastric pain radiating to the back, weight loss, steatorrhea.
• Gastric or esophageal malignancy: Alarm features, advanced age, and positive endoscopic findings raise suspicion.
• Medication-induced dyspepsia: NSAIDs, aspirin, iron supplements, bisphosphonates, potassium chloride, antibiotics, GLP-1 receptor agonists, and many others.
• Hepatic and splenic disorders: Hepatomegaly, splenomegaly, or subcapsular processes may produce epigastric or upper abdominal discomfort.
• Cardiac disease: Atypical angina or inferior wall ischemia can present as epigastric pain or burning. This should be considered particularly in patients with cardiovascular risk factors.

The Role of Helicobacter pylori in Functional Dyspepsia

H. pylori occupies a unique position in the Rome IV framework. It is the only identified treatable factor that may resolve dyspeptic symptoms in a meaningful subset of patients. International guidelines, including those from the American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), and the Maastricht/Florence consensus, recommend testing for and treating H. pylori in all patients with uninvestigated dyspepsia (the "test-and-treat" strategy), as well as in those with functional dyspepsia diagnosed after endoscopy.

The mechanism by which H. pylori causes dyspepsia is not fully understood. Proposed pathways include gastric mucosal inflammation (antral-predominant gastritis with acid hypersecretion, or corpus-predominant gastritis with acid hyposecretion), altered gastric motility, sensitization of gastric afferents, and modulation of neurohumoral signaling. Not all infected individuals develop dyspepsia, and eradication does not benefit all infected dyspeptic patients, suggesting that host susceptibility factors and the specific inflammatory response determine outcomes.

When H. pylori eradication leads to sustained (at least 6-month) resolution of dyspeptic symptoms, Rome IV reclassifies the condition as "H. pylori-associated dyspepsia" rather than functional dyspepsia. This distinction acknowledges that a treatable organic factor was identified and addressed.

Management Strategies

Management of functional dyspepsia is stepwise, individualized, and often multimodal. Because no single therapy is universally effective, treatment selection should be guided by the predominant symptom pattern (PDS versus EPS versus overlap), the presence of identifiable contributing factors (e.g., H. pylori, dietary triggers, psychological comorbidity), and patient preferences.

Patient Education and Reassurance

A strong therapeutic relationship begins with clear communication about the nature of functional dyspepsia. Patients benefit from understanding that their condition is a recognized medical disorder with identifiable pathophysiological mechanisms, not "all in their head." Explaining the concept of gut-brain interaction in accessible terms can help patients feel validated and more engaged in their care. Reassurance about the benign prognosis (no increased risk of cancer or other serious organic disease) can reduce anxiety and healthcare-seeking behavior.

Dietary Modifications

• Smaller, more frequent meals: Large meals provoke greater gastric distension and may overwhelm impaired accommodation. Eating five to six smaller meals throughout the day rather than three large meals can reduce postprandial symptoms.
• Low-fat diet: Dietary fat delays gastric emptying, triggers CCK release, and can exacerbate postprandial fullness, nausea, and early satiation. Reducing fat intake is often one of the most effective dietary interventions for PDS.
• Avoidance of individual triggers: Common triggers include coffee, alcohol, spicy foods, carbonated beverages, and wheat-based products. An elimination and reintroduction approach can help identify patient-specific triggers.
• Low-FODMAP diet: While primarily studied in IBS, a low-FODMAP diet may benefit some functional dyspepsia patients, particularly those with overlapping bloating and altered bowel habits.

Helicobacter pylori Eradication

All patients with functional dyspepsia who test positive for H. pylori should be offered eradication therapy. Standard first-line regimens include bismuth quadruple therapy, concomitant therapy, or clarithromycin-based triple therapy (in regions with low clarithromycin resistance). Eradication should be confirmed with a post-treatment urea breath test or stool antigen test performed at least four weeks after completion of therapy and at least two weeks after discontinuation of PPI therapy.

Acid-Suppressive Therapy

• Proton pump inhibitors (PPIs): PPIs are among the most commonly prescribed medications for functional dyspepsia. They appear to be most effective for EPS (epigastric pain and burning) and less so for PDS. A meta-analysis demonstrated a number needed to treat (NNT) of approximately 10 to 14 for PPIs versus placebo in functional dyspepsia. Standard-dose PPI therapy (e.g., omeprazole 20 mg, esomeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg) for four to eight weeks is a reasonable first-line pharmacological trial for patients with EPS or overlap dyspepsia.
• H2-receptor antagonists (H2RAs): Less potent than PPIs but may be effective in some patients, particularly those who prefer not to take PPIs or who experience PPI-related side effects. H2RAs are sometimes used as maintenance therapy after initial PPI response.
• Potassium-competitive acid blockers (P-CABs): Vonoprazan and other P-CABs represent a newer class of acid-suppressive agents with faster onset and potentially greater efficacy than PPIs; their role in functional dyspepsia is being explored.

Prokinetic Agents

Prokinetics are particularly relevant for the PDS subtype, where impaired gastric motility is often a contributing factor:

• Metoclopramide: A dopamine D2 receptor antagonist with prokinetic and antiemetic properties. Effective but limited by the risk of extrapyramidal side effects and tardive dyskinesia with long-term use. The FDA recommends use for no more than 12 weeks.
• Domperidone: A peripherally acting D2 receptor antagonist with fewer central nervous system side effects than metoclopramide. Not available in the United States but widely used in Europe, Asia, and Latin America. Carries a small risk of QT prolongation.
• Itopride: A D2 antagonist and acetylcholinesterase inhibitor with prokinetic properties. Available in Asia and some other regions; has shown efficacy in clinical trials.
• Acotiamide: A novel prokinetic that enhances acetylcholine release by inhibiting acetylcholinesterase at the muscarinic nerve terminal. Approved in Japan for PDS and has shown efficacy in improving postprandial fullness and early satiation.
• Prucalopride: A selective 5-HT4 receptor agonist primarily indicated for chronic constipation but under investigation for its effects on gastric emptying and accommodation in functional dyspepsia.

Central Neuromodulators

When first-line therapies (acid suppression, prokinetics, H. pylori eradication) are insufficient, central neuromodulators that modulate the brain-gut axis are increasingly used:

• Tricyclic antidepressants (TCAs): Low-dose amitriptyline (10 to 50 mg at bedtime) is the best-studied neuromodulator for functional dyspepsia. The landmark FNDACT trial demonstrated that amitriptyline was superior to placebo for functional dyspepsia, particularly for epigastric pain (EPS). TCAs are thought to work through modulation of visceral pain pathways, anticholinergic effects on motility, and central anxiolytic/analgesic properties, rather than through their antidepressant mechanism at these low doses.
• Mirtazapine: A noradrenergic and specific serotonergic antidepressant (NaSSA) that has shown benefit in functional dyspepsia, particularly in patients with weight loss, nausea, or early satiation. It may improve gastric accommodation and has anxiolytic and appetite-stimulating properties.
• Buspirone: A 5-HT1A receptor agonist and anxiolytic that enhances gastric accommodation and may reduce postprandial symptoms. Typically dosed at 10 mg three times daily before meals.
• SSRIs and SNRIs: Less well-studied in functional dyspepsia than TCAs, but may be considered in patients with prominent anxiety or depression. Escitalopram did not demonstrate superiority over placebo in the FNDACT trial, suggesting SSRIs may be less effective than TCAs for this condition.

Psychological Therapies

Psychological therapies targeting the brain-gut axis have demonstrated efficacy in functional dyspepsia, particularly in patients with psychological comorbidity or those who have not responded to pharmacological management:

• Cognitive behavioral therapy (CBT): Restructures maladaptive illness beliefs, reduces symptom-related hypervigilance, and improves coping strategies. Several randomized trials have shown benefit in functional dyspepsia.
• Gut-directed hypnotherapy: Uses hypnotic techniques to modulate visceral sensitivity, reduce symptom perception, and promote relaxation. Evidence from IBS trials is strong, and emerging data support its use in functional dyspepsia.
• Mindfulness-based stress reduction (MBSR): May help patients develop a non-reactive awareness of somatic sensations, reducing the emotional distress associated with symptoms.

Complementary and Emerging Therapies

• STW 5 (Iberogast): A multi-herbal preparation containing nine botanical extracts that has shown efficacy in multiple randomized controlled trials for functional dyspepsia. It may improve gastric accommodation, reduce visceral hypersensitivity, and modulate gastric motility.
• Rikkunshito: A traditional Japanese herbal medicine (Kampo) that has demonstrated prokinetic and appetite-stimulating effects in clinical trials, particularly for PDS.
• Peppermint oil and caraway oil: The combination has shown efficacy in functional dyspepsia trials, likely through smooth muscle relaxation and modulation of visceral sensitivity.

Using the Rome IV Functional Dyspepsia Calculator

The Rome IV Functional Dyspepsia diagnostic criteria calculator is a clinical decision-support tool designed to systematically evaluate whether a patient meets the Rome IV criteria for functional dyspepsia (B1) and, if so, to classify the subtype. The calculator prompts the clinician to assess each of the four cardinal symptoms, the organic disease exclusion criterion, and both temporal requirements individually.

The calculator evaluates the following seven elements:

1. Whether bothersome postprandial fullness is present.
2. Whether bothersome early satiation is present.
3. Whether bothersome epigastric pain is present.
4. Whether bothersome epigastric burning is present.
5. Whether there is no evidence of organic, systemic, or metabolic disease likely to explain the symptoms.
6. Whether the criteria have been fulfilled for the last 3 months.
7. Whether symptom onset occurred at least 6 months before the current evaluation.

At least one of the four cardinal symptoms must be endorsed, along with the organic disease exclusion and both temporal criteria, for a positive diagnosis. When criteria are met, the calculator further classifies the subtype:

• Postprandial Distress Syndrome (PDS, B1a): If postprandial fullness and/or early satiation are endorsed.
• Epigastric Pain Syndrome (EPS, B1b): If epigastric pain and/or epigastric burning are endorsed.
• Overlap PDS + EPS: If symptoms from both groups are endorsed.

If criteria are not fully met, the calculator identifies which specific requirements are unmet and suggests consideration of alternative diagnoses. This tool is intended for educational and clinical decision-support purposes and does not replace comprehensive clinical assessment, appropriate investigation, or the exercise of clinical judgment by a qualified healthcare provider.

Overlap with Other Disorders of Gut-Brain Interaction

Functional dyspepsia commonly coexists with other DGBI. The overlap between functional dyspepsia and IBS is particularly well-documented, with 30% to 50% of patients meeting criteria for both conditions. This co-occurrence is thought to reflect shared pathophysiological mechanisms, including visceral hypersensitivity, altered motility, low-grade mucosal inflammation, microbiota dysbiosis, and central nervous system dysfunction.

Functional dyspepsia also overlaps with GERD (30% to 40% overlap), functional heartburn, and belching disorders. The frequent coexistence of upper and lower GI functional disorders underscores the systemic nature of gut-brain interaction abnormalities and the importance of evaluating the entire GI symptom profile when assessing a patient with dyspepsia.

Extra-intestinal functional conditions, including fibromyalgia, chronic fatigue syndrome, interstitial cystitis/painful bladder syndrome, temporomandibular joint disorder, and chronic headache, are also more prevalent in functional dyspepsia patients than in the general population. This multi-system overlap supports the hypothesis that central sensitization and altered stress-response systems are common to many chronic functional pain conditions.

Prognosis and Natural History

Functional dyspepsia is a chronic, relapsing condition. Longitudinal studies suggest that approximately one-third of patients experience symptom resolution over one to two years, one-third have persistent but stable symptoms, and one-third have a fluctuating course with periods of exacerbation and remission. Some patients transition between FD subtypes or develop overlapping IBS over time.

Functional dyspepsia does not increase the risk of gastric cancer, peptic ulcer disease, or other serious organic conditions (assuming H. pylori has been appropriately addressed). Reassurance about the benign long-term prognosis is a cornerstone of management and can itself reduce symptom burden and healthcare utilization.

Quality of life is significantly impaired in functional dyspepsia, particularly in patients with overlap subtypes, concurrent psychological disorders, or severe early satiation with weight loss. Comprehensive, patient-centered management that addresses biological, psychological, and social dimensions of the illness offers the best prospect for sustained improvement.